Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo
| Autor: | James M. McKenney, Krishnaji R. Kulkarni, Poulabi Banerjee, Corinne Hanotin, Peter P. Toth, Eli M. Roth, Seth S. Martin, Steven R. Jones, Parag H. Joshi, Sara Hamon |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Clinical chemistry Endocrinology Diabetes and Metabolism Lipoproteins Clinical Biochemistry Hypercholesterolemia 030204 cardiovascular system & hematology Lipoproteins VLDL Placebo Bioinformatics Antibodies Monoclonal Humanized Gastroenterology PCSK9 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endocrinology Double-Blind Method Internal medicine Medicine Humans 030212 general & internal medicine Triglycerides Alirocumab Hypercholesterolaemia Randomized Controlled Trials as Topic Biochemistry medical business.industry Cholesterol Research Biochemistry (medical) Lipoprotein subfraction Antibodies Monoclonal Cholesterol LDL Middle Aged Vertical auto profile Lipid Metabolism chemistry VAP lipids (amino acids peptides and proteins) Female business Lipoproteins HDL Lipoprotein Lipidology |
| Zdroj: | Lipids in Health and Disease |
| ISSN: | 1476-511X |
| Popis: | Background The effect of alirocumab on potentially atherogenic lipoprotein subfractions was assessed in a post hoc analysis using the vertical auto profile (VAP) method. Methods Patients from three Phase II studies with low-density lipoprotein cholesterol (LDL-C) ≥2.59 mmol/L (100 mg/dL) at baseline on stable statin therapy were randomised to receive subcutaneous alirocumab 50–150 mg every 2 weeks (Q2W) or 150–300 mg every 4 weeks (according to study) or placebo for 8–12 weeks. Samples from patients treated with alirocumab 150 mg Q2W (n = 74; dose common to all three trials) or placebo (n = 71) were analysed by VAP. Percent change in lipoprotein subfractions with alirocumab vs. placebo was analysed at Weeks 6, 8 or 12 using analysis of covariance. Results Alirocumab significantly reduced LDL-C and the cholesterol content of subfractions LDL1, LDL2 and LDL3+4. Significant reductions were also observed in triglycerides, apolipoproteins CII and CIII and the cholesterol content of very low-density, intermediate-density, and remnant lipoproteins. Conclusion Alirocumab achieved reductions across a spectrum of atherogenic lipoproteins in patients receiving background statin therapy. Trial registration Clinicaltrials.gov identifiers: NCT01288443, NCT01288469, NCT01266876 Electronic supplementary material The online version of this article (doi:10.1186/s12944-016-0197-4) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|